Citigroup
RNTX

Citigroup’s Rein Therapeutics RNTX Stock Holding History

Citigroup’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$1 – 6380
2025
Q2 		$1 Buy
+1
New +$2 ﹤0.01% 5621
2022
Q2 		– Sell
-1,506
Closed -$15K – 6750
2022
Q1 		$15K Buy
+1,506
New +$13.6K ﹤0.01% 5340
2018
Q2 		– Sell
-49
Closed -$8K – 7765
2018
Q1 		$8K Sell
49
-263
-84% -$46.9K ﹤0.01% 7120
2017
Q4 		$65K Sell
312
-516
-62% -$124K ﹤0.01% 5992
2017
Q3 		$222K Buy
+828
New +$208K ﹤0.01% 4909

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Citigroup's RNTX Position: Q3 2025 in Review

Citigroup sold out of Rein Therapeutics (RNTX) in Q3 2025, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in RNTX in Q3 2017 and held it in 5 quarters. The position peaked at $222K in Q3 2017. 40 funds tracked by Wall St. Rank hold RNTX as of Q3 2025.

  • Citigroup reported no remaining Rein Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 1 Rein Therapeutics share in Q3 2025, an estimated $1.
  • Citigroup first reported a position in Rein Therapeutics in Q3 2017 and held it in 5 quarters.
  • Citigroup's Rein Therapeutics position peaked at $222K in Q3 2017.
  • 40 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.